SynthesisChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025
Pediatric low-grade brainstem glioma: a review of current diagnosis and treatment paradigms in the molecular era.
Synthesis in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric low-grade brainstem gliomas (pLGBG) are a rare and understudied diagnosis. The advent of molecular diagnostics has revolutionized pediatric neuro-oncology, and its application in the setting of pLGBG continues to grow. The aim of this review was to systematically summarize the current literature regarding how molecular data has impacted pLGBG diagnosis and treatment to date.
methodsSearches of multiple electronic databases from inception to January 2025 were conducted following PRISMA guidelines. Articles were screened against pre-specified criteria, and then, those that satisfied criteria were summarized.
resultsA total of 15 studies were included in this review. There were ten studies relating to molecular status to diagnosis, three studies relating molecular status to targeted treatment, and single studies relating molecular status to surgical and chemotherapy outcomes. No studies relating molecular status to radiation therapy outcomes were found. In terms of diagnosis, the most commonly reported molecular alteration in pLGBG was KIAA1549-BRAF fusion. Other prominent molecular alterations reported included BRAF V600E mutation and FGFR alterations. Targeted therapy outcomes were limited to case reports, which showed promising results using BRAF and MEK inhibition. There were many active clinical trials investigating the role of targeted therapy further in this setting using molecular data.
conclusionsThe use of molecular diagnostics is emerging to be promising in the setting of pLGBG, which historically has been under investigated due to its anatomical location. Preliminary studies indicate that knowledge of molecular status can influence both diagnosis and treatment. Targeted treatment is the most exciting avenue for this, with exciting anecdotal data in the literature, and multiple clinical trials underway at this time.
Indexed as
Identifiers
40824451What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.